1,097 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by World Investment Advisors LLC

World Investment Advisors LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 1,097 shares of the biotechnology company’s stock, valued at approximately $393,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. increased its stake in United Therapeutics by 1.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after buying an additional 33 shares during the period. Toronto Dominion Bank increased its position in shares of United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares during the last quarter. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its position in shares of United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. increased its position in shares of United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 119,340 shares of company stock valued at $44,765,530. Company insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on UTHR. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Jefferies Financial Group boosted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Finally, LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Up 1.8 %

United Therapeutics stock opened at $379.69 on Wednesday. The firm has a 50-day moving average price of $370.88 and a two-hundred day moving average price of $344.17. The firm has a market capitalization of $16.95 billion, a price-to-earnings ratio of 16.68, a PEG ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.38 EPS. Research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.